LYRA LANTERN PHASE 2 STUDY RESULTS FOR LYR-210 IN CRS

Results of the LANTERN Phase 2 randomized controlled study evaluating the safety and efficacy of LYR-210 in chronic rhinosinusitis (CRS) were presented at Combined Otolaryngology Spring Meetings (COSM) 2021, by Anders Cervin of the University of Queensland, Australia, a key LANTERN investigator.

In this video presentation, Dr. Robert Kern, Professor and Chairman, Department of Otolaryngology – Head & Neck Surgery, Feinberg School of Medicine, Northwestern University, shares the data presented at COSM along with additional data from the LANTERN study, which Lyra has reported separately.

Data slides are available here

 

Additional LYR-210 six-month long-term data and PK data were presented at the American Rhinologic Society (ARS) Annual Meeting in October 2021. See these results:

Press release
Data slides

Back to Top